TriSalus Life Sciences (Nasdaq:TLSI) announced today that it launched its new TriNav FLX infusion system. TriNav FLX features enhanced trackability and significantly expands the company’s existing TriNav portfolio of products. It offers interventional radiologists more options to select the right product for the right patient, TriSalus said in a news release. According to TriSalus, the […]
trisaluslifesciences
TriSalus releases positive data for its catheter-based drug delivery tech
TriSalus Life Sciences today announced positive clinical results for its Pressure-Enabled Regional Immuno-Oncology technology. The company, currently in the process of going public through a SPAC merger, filed a presentation for investors. It features information regarding its ongoing PERIO 01 and PERIO 02 clinical studies. The studies evaluate the TriNav pressure-enabled drug delivery technology for […]
TriSalus enrolls first patient in pressure-enabled drug delivery trial for treating melanoma
TriSalus Life Sciences announced today that it enrolled the first patient in its clinical study of a treatment for metastatic uveal melanoma. The PERIO-01 clinical study evaluates SD-101, an investigational toll-like receptor 9 (TLR9) agonist in adults with metastatic uveal melanoma through intravascular administration into uveal melanoma liver metastasis lesions in combination with checkpoint inhibitors […]
TriSalus, University of Texas to collaborate on solid tumor treatment study
TriSalus Life Sciences and the University of Texas today announced a collaboration to evaluate the treatment of solid tumors. The Texas MD Anderson Cancer Center and TriSalus will collaborate on treatments for tumors of the pancreas and liver by integrating interventional delivery of SD-101, an investigational toll-like receptor 9 (TLR9) agonist, in combination with checkpoint […]
TriSalus Life Sciences names chief commercial officer
TriSalus today said it appointed Trevor McCaw as chief commercial officer. The chief commercial officer position is new within TriSalus, and McCaw will report directly to CEO Mary Szela. He will be responsible for integrating the company’s therapeutics and innovative drug delivery systems to provide a total solution for patients. Prior to joining the company, […]
TriSalus names new chief medical officer
TriSalus today said it appointed Steven Katz as chief medical officer. Katz will be responsible for overseeing the company’s clinical development strategy in the treatment of solid tumors. He has served as TriSalus’s chief medical advisor and chairperson of its scientific advisory board since 2018. “We are thrilled to have Steven join TriSalus as a […]
TriSalus launches TriNav Infusion System
TriSalus this week launched its TriNav Infusion System. The infusion system is powered by the company’s Pressure-Enabled Drug Delivery (PEDD) approach with SmartValve technology and is designed to help with the infusion barriers that can limit therapeutic uptake in solid tumors. It gives interventional radiologists intravascular tumor access and improved traceability, compatibility with standard angiographic […]
TriSalus touts data for pressure-enabled drug-delivery tech
TriSalus Life Sciences touted results today from a Phase Ib trial of its pressure-enabled drug-delivery tech for immunotherapy. The company reported that delivering a concentrated dose of CAR-T cells at the site of a solid tumor using its technology was safe and contributed to positive clinical results. In the early-stage trial, five patients with carcinoembryonic […]
